Valeant Pharmaceuticals and Kadmon Pharmaceuticals have entered two strategic agreements for the development and commercialization of taribavirin and the marketing of ribavirin in the treatment of viral diseases, including hepatitis C virus (HCV). Under the first agreement, Kadmon has an exclusive, worldwide license to taribavirin, excluding Japan, in exchange for an upfront payment of $5 million, development milestones, and royalties on future net sales. Under a separate agreement, Valeant paid...